Diligence memo · auto-generated · as of July 2, 2026
Digital Therapeutics, Inc.
Digital Therapeutics, Inc. looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
Digital Therapeutics, Inc. operates in Pharma, based in New York.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Digital Therapeutics, Inc. has raised $124M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $50M on 2023-12-21.
Most recent recorded round closed around 2023-12-21.
Valuation (modeled)modeled
Provath models Digital Therapeutics, Inc. at approximately $531M (range $164M–$868M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.84× the median modeled value of Series C Pharma companies in 2022–2024 (7 peers) — value vs value, same stage and era. Within the normal band (84% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 16 months.
Last raise 2.5 yr ago; this sector typically re-raises about every 16 months.
Slightly overdue versus sector cadence.
The last round stepped up 4.4× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 92% of Pharma peers (310 compared).
Modeled value ranks above 86% of those peers.
Closest niche peers: Circle Pharma, Inc., Averna Therapeutics Inc., Soleno Therapeutics Inc, Progentos Therapeutics, Inc., Intrinsic Therapeutics Inc.
Peoplefiled
8 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.